Interactive Brokers shares jump as it secures spot in S&P 500
On Wednesday, JMP Securities sustained its Market Outperform rating on AMN Healthcare Services Inc . (NYSE:AMN) shares, with a continued price target of $33.00. Currently trading at $23.80, near its 52-week low of $22.46, InvestingPro analysis suggests the stock is undervalued. The firm’s analysts believe that despite anticipating some short-term volatility in the sector, there is a positive outlook for the stabilization of nursing and allied health professions as the year progresses.
The analysts’ optimism is based on the expectation of market conditions for healthcare staffing improving in the latter half of 2025. While revenue declined 21.26% in the last twelve months, InvestingPro data shows strong free cash flow yield of 26%, suggesting financial resilience. They predict that the current challenges faced by the industry will give way to more stable conditions, which will benefit AMN Healthcare in the long run.
JMP Securities has derived the $33.00 price target for AMN Healthcare by applying a 10-times multiple to its projected 2025 adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). This valuation reflects a confident view of the company’s future financial performance.
AMN Healthcare is a leading healthcare staffing company that provides workforce solutions and staffing services to healthcare facilities across the nation. The company’s services are critical in meeting the demand for healthcare professionals in various specializations.
The reiteration of the Market Outperform rating and price target by JMP Securities indicates a positive stance on AMN Healthcare’s stock, as the firm anticipates the company to perform well against the backdrop of an evolving healthcare staffing industry. With a market capitalization of $909 million and analysts expecting profitability this year, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports.
In other recent news, AMN Healthcare reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an adjusted earnings per share (EPS) of $0.75, compared to the forecast of $0.49. The company achieved revenues of $735 million, exceeding the expected $694.36 million, marking a notable performance in a challenging market. Despite a year-over-year revenue decline of 21% to $3 billion, the results were driven by higher-than-expected strike revenue and increased order flow in the Allied and Locum tenens divisions. JMP Securities adjusted AMN Healthcare’s price target to $33 from $34 while maintaining a Market Outperform rating, reflecting the company’s solid performance despite the challenges in the healthcare staffing industry.
UBS analysts maintained a Neutral rating on AMN Healthcare with a price target of $30, emphasizing the company’s focus on debt reduction through 2025. AMN Healthcare ended 2024 with a leverage ratio of 3.0x, and management indicated that the financial position is not yet conducive to pursuing major acquisitions. Benchmark analysts reiterated a Hold rating, noting the company’s stable position in the healthcare staffing market amidst ongoing challenges. They highlighted that AMN Healthcare’s business units are showing greater stability, with travel nurse utilization and bill rates approaching normal levels.
The company launched new technology platforms, such as the Shiftwise Flex (NASDAQ:FLEX) VMS platform and the Passport app, to enhance service delivery and job matching. These efforts reflect AMN Healthcare’s strategic focus on innovation and operational efficiency, positioning it well in the competitive healthcare staffing market. As AMN Healthcare continues to navigate industry challenges, analysts will closely monitor its performance and strategic initiatives in the coming months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.